{
    "clinical_study": {
        "@rank": "88896", 
        "arm_group": {
            "arm_group_label": "Canagliflozin + cyclosporine", 
            "arm_group_type": "Experimental", 
            "description": "Each volunteer will receive canagliflozin (JNJ-28431754) once daily on Days 1 through 8 with a single dose of cyclosporine on Day 7."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine how a single dose of cyclosporin affects the\n      pharmacokinetics (ie, how the body affects the drug) of multiple doses of canagliflozin\n      (JNJ-28431754). The safety and tolerability of canagliflozin will also be assessed in\n      healthy volunteers."
        }, 
        "brief_title": "A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers", 
        "completion_date": {
            "#text": "April 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This study will be an open label (all volunteers and study staff know the identity of\n      assigned treatments), single-center, multiple-dose study to determine how cyclosporin (a\n      drug which reduces the activity of a patient's immune system) affects the pharmacokinetics\n      of canagliflozin (a drug currently being investigated for the treatment of type 2 diabetes\n      mellitus). The study will consist of 3 phases: a screening phase, an open-label treatment\n      phase, and an end-of study (or follow-up) phase. Each volunteer will participate in the\n      study for approximately 47 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have body mass index between 18 and 30 kg/m2 (inclusive), and body weight not\n             less than 50 kg\n\n          -  If a woman, must be either postmenopausal, defined as no spontaneous menses for at\n             least 18 months or amenorrhea for at least 6 months or surgically sterile (have had a\n             hysterectomy, or tubal ligation)\n\n        Exclusion Criteria:\n\n          -  History of smoking or use of nicotine-containing substances within the previous 2\n             months\n\n          -  Have had history of or current medical illness considered to be clinically\n             significant by the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718652", 
            "org_study_id": "CR017926", 
            "secondary_id": [
                "28431754DIA1031", 
                "2010-021854-21"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Canagliflozin + cyclosporine", 
                "description": "One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.", 
                "intervention_name": "Canagliflozin (JNJ-28431754)", 
                "intervention_type": "Drug", 
                "other_name": "JNJ-28431754"
            }, 
            {
                "arm_group_label": "Canagliflozin + cyclosporine", 
                "description": "Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.", 
                "intervention_name": "Cyclosporine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclosporins", 
                "Cyclosporine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Healthy", 
            "Canagliflozin (JNJ-28431754)", 
            "Pharmacokinetics", 
            "Cyclosporine"
        ], 
        "lastchanged_date": "November 22, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerpen", 
                    "country": "Belgium"
                }
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Single Sequence Study to Assess the Effect of a Single Dose of Cyclosporine on the Steady-State Pharmacokinetics of JNJ-28431754 (Canagliflozin) in Healthy Adult Subjects", 
        "overall_official": {
            "affiliation": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
            "last_name": "Johnson & Johnson Pharmaceutical Research & Development,L.L. C. Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Comparison of the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve (AUC) of canagliflozin (JNJ-28431754) (measures of the body's exposure to canagliflozin) before and after administration of a single dose of cyclosporine. This will be used to determine whether there is a pharmacokinetic interaction between cyclosporine and canagliflozin.", 
            "measure": "Plasma concentrations of canagliflozin (JNJ-28431754)", 
            "safety_issue": "No", 
            "time_frame": "Day 7 and Day 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718652"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The number of volunteers with adverse events as a measure of safety and tolerability", 
            "safety_issue": "No", 
            "time_frame": "Up to 47 days"
        }, 
        "source": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}